Decisions 23rd July 2013


Recent JFG Decisions

 

At the meeting on the 23rd July 2013 the following decisions / changes to the formulary were agreed

 

New Drug Requests

Approved

Mirabegron 

NICE TA 290 – will be included on formulary in line with implementation of NICE TAs (90 days from publication) – TLS Blue after patient has tried bladder training and two anti-muscarinic drugs.

 

Denosumab for men

Clinically appropriate (clinical effectiveness and equity of access) for inclusion in formulary in line with TA 204. TLS amber. SCP to be updated.

 

Voractiv®  (rifampicin, isoniazid, pyrazinamide and ethambutol)

Added to formulary - useful addition to reduce the pill burden, TLS Red.

 

Dermovate with 40% polypropylene

Added to formulary due to its place in therapy relative to available treatments for use in severe hyperkeratotic psoriasis and eczema of the palms and / or soles for 4 weeks.  TLS Red specialist consultant use only.  

 

Not approved, More information requested

Ozurdex® (dexamethasone intravitreal implant)

Clinically appropriate to add to formulary for licenced indication (one implant only) but financial modelling not submitted to show a cost neutral or cost saving position. The JFG was unable to approve the application at this time.

 

Lixisenatide

Clinical non-inferiority to exenatide was agreed however superiority data was lacking. The JFG would like to further explore the cost-effectiveness of lixisenatide. The application was not approved at this time.

 

Specialised Commissioning

None

 

Other Decisions

None

 

 

 

Last updated by: on 09-09-2013 16:58